Index

A
AA. See Alopecia areata
Abels, C., 10, 14, 118
Abramovits, W., 65, 67, 69–72

Acne
initial consultation and treatment
antibiotics, 109–170
disadvantages, ALA-PDT, 170
ice packs, 170
light therapy, 170
PDT therapy, 170
IPL, 169
oral isotretinoin, 169
Propionibacterium acnes, 169
sebaceous follicles, 169
skin penetration, 169
treatment (see Photodynamic therapy (PDT), acne)

Actinic keratoses (AKs)
advantages/disadvantages, ALA-PDT, 9
ALA and MAL, 85
clinical presentation and diagnosis, 7–8
combination therapy, 15
definition and clinical features, 61–62
epidemiology and causes, 7, 62
histopathology, 8
IPL, 84
keratinization disorder, 166
malignant degeneration, 166
malignant lesion, 166
MAL-PDT (see MAL-PDT, AKs)
paths, 166
PDT procedure
aggressive protocols, 168
IPL settings and activation, 167
Levulan, 167
moisturizers and sunscreens, 167
placebo and light, 168
photorejuvenation, 15–16
prevention
5 fluorouracil, 140
imiquimod, 140
MAL, 146
transplant patients, 141
published clinical studies, 10–11
risk factors, evaluation, 139–140
SCC and BCC, 62
treatment and management, 62
treatment options, 8–9
treatment results, ALA-PDT
blue light, 12–13
broad band/visible light sources, 14–15
green light, 13
laser sources, red light, 14
red light sources, 13–14
violet light, 9, 12
yellow-orange light, 13

Actinic porokeratosis. See Actinic keratoses (AKs)
Adair, J., 35

Age related macular degeneration (ARMD)
description, 133
serous/lipid exudate leakage, 133
verteporfin and anti-VEGF, 133
Aghassi, D., 32, 33, 36
Akir, S.B.M., 61
AKs. See Actinic keratoses
ALA. See Aminolevulinic acid
5-ALA. See 5-aminolevulinic acid
ALA methyl ester
acne treatment, 93
percutaneous penetration, 94
pre-treatment, 94
ALA-PDT controlled study, 73–74
ALA-photodynamic therapy (ALA-PDT)
acne, 169–170
advantages/disadvantages for AKs, 9
AK
keratinization disorder, 166
malignant degeneration, 166
malignant lesion, 166
paths, 166
and photorejuvenation, 23–24
procedure, 166–168
benefits, 26
initial consultation
cleansing and pretreatment, 162–163
light-based therapies, 162
protective clothing and sunscreen, 163
light sources
BLU-U®, 163–164
disadvantages, 163

M.H. Gold (ed.), Photodynamic Therapy in Dermatology,
ALA-photodynamic therapy (ALA-PDT) (continued)

- IPL systems, 164
- optimal wavelength, 163
- photorejuvenation, 16
- treatments, 163

Patient selection
- exclusion criteria, 21
- OTR population, 21–22

Photorejuvenation
- blue light, 16, 19
- IPL, 19–21
- PDL, 21
- red light, 19

Procedure
- Levulan, 164
- light therapy, 164
- pain medication, 165
- side effects, 164
- soap and sunscreen, 164–165
- sun-damaged skin, 165
- white vinegar solution, 165

Published clinical studies
- AKs, 10–11
- photorejuvenation, 17–18
- safety, adverse effects and complications, 24–26
- sensitizers, 163
- sun-damaged skin, 162
- treatment protocol
  - follow-up, 23
  - incubation time, 22–23
  - light sources, 23
  - patient comfort and photoprotection, 23
  - skin preparation, 22
- treatment results for AKs
  - blue light, 12–13
  - broad band/visible light sources, 14–15
  - green light, 13
  - laser sources, red light, 14
  - red light sources, 13–14
  - violet light, 9, 12
  - yellow-orange light, 13

Alexander Mosse, C., 133
Alexiades-Armenakas, M.R., 11, 13, 21, 34, 35, 84, 115, 170, 181
Alopecia areata (AA) treatment
- microneedle technique, 119
- recalcitrant, 119
- Alster, T.S., 17, 20, 49
- Altimoglu, E., 35
- Altschuler, G.B., 35, 36

5-Aminolevulinic acid (5-ALA)
- acne treatments
  - blue light, 34
  - blue light vs. blue light alone, 35
  - diode laser, 36
  - epidermal cells, 32
  - grade and lesion data, 34
  - ICG, 35–36
  - intense pulsed light (IPL), 34
  - intraleisional PDT, 35
- mechanism, 33
- methylene blue, 36
- PDL activation, 34, 35
- PpIX, 32–33
- sebaceous glands, 36–37
- incubation period, 40–41
- IPL, 84
- light sources, 37–38
- metabolic pathway, 32
- PDT, 31, 88
- photosensitizers, 38–40
- protocols
  - clinical reflections, 42–43
  - economic factors, 42
  - postoperative care, 41–42
- pulsed dye laser, 35

Aminolevulinic acid (ALA)
- acne treatment, 93
- addition, liquid culture, 130–131
- application and structure, 124
- description, 5
- emulsifying ointment, 132
- fungal treatment, 130
- HS treatment
  - blue light sessions vs. IPL, 59
  - drug incubation time, 57
  - PpIX accumulation, 57
  - methyl ester, 3, 135
  - Metvix cream, 131
  - *M. marinum*, in vitro incubation, 129
  - oral, 106
- PDT
  - evaluation, psoriasis, 106
  - vs. MAL-PDT, 59
- mechanism, 6
- penetration, stratum corneum, 106, 108
- photosensitivity, 133
- phototoxicity, 3
- placebo group, 99
- PpIX absorption spectrum, 2–3, 57, 58
- primary/adjunctive therapy, 128
- prodrug photosensitizer agent, 2
- radiodermatitis, 134
- short contact mode, 57
- skin cancer prevention
  - hairless mice, 141
  - immune response, 140
  - Kerastick™, 144
- non immunosuppressed patients, 142
- outside face, 144
- pain management, 143
- PDT protocol, 145–146
- porphyrins accumulation, 141
- treatment
  - AA, 119
  - Darier’s disease, 119–120
  - GA, 118–119
  - Lichen sclerosis, 113–116
  - Morphea/Scleroderma, 114, 117
  - NLD, 118
nonhyperkeratotic AKs, 57
Sarcoidosis, 118
Vitiligo, 117
verrucae and molluscum lesions, 99
Ammann, R., 99
Anderson, R.R., 32, 33, 36
Annemans, L., 65, 68–70, 72
Apalla, Z., 113, 115
Arenberger, P., 118
Arriaga-Palomo, D., 113, 115
ARMD. See Age related macular degeneration
Arndt, K.A., 17, 20, 84
Arpaia, N., 78
Arrazola, J.M., 112
Atkin, D.H., 9, 11–13, 16, 17
Auler, H., 2
Avram, D.K., 11, 17, 19
Babilas, P., 77
Bacterial infections
anti-microbial therapy, 126–127
biofilm role, 127
Erythrasma, 128
Gram (+) and (-) bacteria, 127
leg ulcers
ALA PDT, 128
MRSA, 128
Mycobacterium infections
granulomas, 128
M. marinum, 129
photosensitizers photodynamic activity, 128–129
Staphylococcus aureus, 128
Vibrio vulnificus and MRSA, 127
Banzer, G., 2
Barrett’s esophagus (BE)
adenocarcinomas, 132
Green laser light, 133
PDT use, 133
Basal cell carcinoma (BCC)
CP94, 79
MAL-PDT treatment
cosmetic outcome, 78
placebo, 78
PPIX, 78–79
retrospective analysis, 78
surgery, 78
superficial and nodular, 77
Bashkatov, A., 35, 36
Basset-Seguin, N., 63, 64
Battle, A.M., 150
Baumgartner, R., 113
Bäumler, W., 10, 14
BCC. See Basal cell carcinoma
Beà-Ardebol, S., 115
Benzoporphyrin derivative monoacid ring A (BPD-MA), 185
Berking, C., 118
Berne, B., 65, 68–70, 74
Berner, A., 77
Bhatia, A.C., 17, 20, 65, 67, 69, 70, 84
Bilski, P.J., 184
Biron, J.A., 85
Bissonnette, R., 63, 64, 106, 107, 139
Bjerring, P.A., 149, 177, 184
Blecha-Thalhammer, U., 111
Boehncke, W.H., 105–107
Bojar, R.A., 33
Borbajo-Martínez, J., 113, 115
Boring, M.M., 18, 20, 50, 85
Boscherhoff, A.K., 117
Bouwes Bavinck, J.N., 142
Bowen’s disease and SCC
cryotherapy, 80
lesions, 80
red LED light, 80
Brow, S.G., 133
BPD-MA. See Benzoporphyrin derivative monoacid ring
A
Braathen, L.R., 63, 64, 67, 69, 70, 72, 99, 151
Bradshaw, V.L., 18, 20, 50, 85
Brancadeo, L., 150
Bridges, T.M., 18, 20, 85
Brown, E.H., 150
Bryden, A., 11, 14, 168
Butler, A.R., 150
C
Caekelbergh, K., 65, 68–70, 72
Cahn, M.M., 53
Calzavara-Pinton, P.G., 10, 14, 66, 69–71
Campbell, S., 26, 66, 69–72
Casas, A., 150
Chang, B.Z., 101
Chang, Y., 32, 33, 36, 93
Chen, D.M., 11, 12, 26, 168
Chen, K., 101
Chignell, C.F., 184
Cho, K.H., 11, 15
Chotzen, V., 48
Christiansen, K., 149
Chronic X-ray dermatitis/radiodermatitis
description, 134
radioscopy, 134
Chung, P.S., 112
Clark, C., 11, 14, 168
Clayton, T.H., 128
Cockerell, C.J., 48
Collen, A.F., 142
Collins, P., 11, 14, 68–70, 106–108, 111
Condylomata acuminata
ALA-PDT vs. conventional CO2 laser therapy, 101
description, 98
PDT, 101
Cook, M.G., 54
Cook, M.J., 184
Córdoba-Guijarro, S., 113, 115
Córdoba, S., 11, 17, 19, 84
Cosmetic photodynamic photorejuvenation
ALA concentrations, 154
Caucasian skin, 154
fluorescence measurement, FDU, 153
guidelines, PDT, 156, 157
increased skin fluorescence, 153
0.5% liposome-encapsulated 5-ALA, 155, 156
optimization PDT procedure
FDU, fluorescence level, 156–157
inter-individual difference, 158
light exposure and 5-ALA removal, 156
maximum fluorescence, 157
skin types differences
5-ALA transformation rate, 155
Asian skin, 155
Caucasian skin vs. Asian skin, 155–156
spraying and fluorescence level, 155–156
spraying period, 155
Costa, C.I., 184
Costanzo, M., 99
Cottrell, W.J., 179
Crommelin, D.J., 184
Cryotherapy-controlled studies, 72–73
Cunliffe, W.J., 33, 91, 93
Curl, R.F., 183
Cutaneous infections
bacterial, 126–129
fungal, 129–131
leishmaniasis (see Cutaneous leishmaniasis)
sarcoïdosis (see Cutaneous sarcoïdosis)
Cutaneous leishmaniasis
ALA PDT treatments, 131
lesion clearance, 131–132
MAL PDT treatments, 131
Cutaneous sarcoïdosis
ALA PDT, 134
description, 134

D
Darier’s disease
clinical and histological improvement, 119
PDT, 119
UVB, 120
Davis, S.A., 65, 67, 69, 70
Dawe, R., 11, 14, 168
de Bruijn, H.S., 111
de Graaf, Y.G., 142
de Leeuw, J., 184
de Vijlder, H.C.
de Wolf, W.F., 111
di Jstra, A.T., 9, 10
Disseminated actinic porokeratosis (DSAP)
description, 132
methyl ALA use, 132
PDT use and role, 132
Dobbs, S.P., 116
Donnelly, R.F., 116
Dougherty, T.J., 2
Dover, J.S., 15, 17, 20, 25, 84
Dragieva, G., 11
DSAP. See Disseminated actinic porokeratosis
Dummer, R., 11
Dunlap, F.E., 11, 13
Dunn, J.M., 133
E
Eide, M.J., 26
Emulsification, 184
Ericson, M.B., 92, 94
Eriksen, P., 151
Ewalds, E., 106–108, 156
F
Fabbrocini, G., 99
Fadel, M., 110, 112, 184
Fai, D., 78
Farber, H.F., 11, 12, 26, 168
Ferdon, M.B., 11, 13
Fergin, P.E., 10, 14, 65, 67, 69–71
Ferguson, J., 150, 153, 168
Fernández-Guarino, M., 112, 115
figge, F.H.J., 2
Fijan, S., 10
Fink-Puches, R., 10, 15
Flesch, F.M., 184
Fluorescence-guided PDT
ALA concentration
AK and BBC, 150–151
creams, 151
MAL and HAL, 151
PpIX fluorescence, 151
cosmetic photodynamic photorejuvenation
ALA concentrations, 154
fluorescence measurement, FDU, 153
guidelines, PDT, 156, 157
increased skin fluorescence, 153, 154
0.5% liposome-encapsulated 5-ALA, 155, 156
optimization, PDT procedure, 156–158
skin types differences, 155–156
spraying period, 154
hand held fluorescence photometer, 149, 150
incubation time
5-ALA, MAL and HAL, 152
1 and 6 h application time, 153
application time, PpIX fluorescence, 152
light exposure, 153
linear correlation, 152
PpIX fluorescence investigation, 153
photometer, 149
phototoxicity, 149
skin fluorescence, 158
skin preparation
AK, 149
PpIX fluorescence, 150
PpIX precursors, 150
Fogh, H., 99
Foley, P., 61, 63, 64
<table>
<thead>
<tr>
<th>Frambach, Y., 65, 67, 69, 70</th>
<th>Harrison, P.V., 128</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fransson, J., 111</td>
<td>Hausman, W., 2</td>
</tr>
<tr>
<td>Freeman, M., 65, 67, 69–71</td>
<td>Hegyi, J., 118</td>
</tr>
<tr>
<td>Fretz, M.M., 184</td>
<td>Hematoporphyrin purified derivative (HPD)</td>
</tr>
<tr>
<td>Fritsch, C., 10, 13, 67, 69, 70, 72, 150, 151</td>
<td>porphyrin subunits and by-products, 2</td>
</tr>
<tr>
<td>Frohn-Nilsson, M., 93</td>
<td>PpIX, 3</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Fungal infection</td>
<td></td>
</tr>
<tr>
<td>blood disinfection and photosensitizers, 129</td>
<td></td>
</tr>
<tr>
<td><em>Candida albicans</em>, 130</td>
<td></td>
</tr>
<tr>
<td>chemical groups and phenothiazines, 130</td>
<td></td>
</tr>
<tr>
<td><em>Cryptococcus neoformans</em>, 130</td>
<td></td>
</tr>
<tr>
<td>dermatophytes strains, 130</td>
<td></td>
</tr>
<tr>
<td>onychomycosis, 131</td>
<td></td>
</tr>
<tr>
<td><em>Trichophyton rubrum</em>, 130–131</td>
<td></td>
</tr>
<tr>
<td>Funk, J., 93</td>
<td></td>
</tr>
</tbody>
</table>

**G**

GA. See Granuloma annulare

Galzavara-Pinton, P.G., 9, 19

Gambles, B., 11, 14

García-Morales, I., 112

Gardlo, K., 67, 69, 70, 72, 151

Garretson, C., 105

Gavrilovic, J., 184

Genina, E., 35, 36

Georgiou, S., 101

Geronemus, R.G., 11, 13, 21, 65, 67, 69–72, 84

Gerritsen, M.J., 106–108, 112, 156

Giercksky, K.E., 77

Gilbert, D.J., 11, 15, 161, 167

Glazer, S.D., 10, 12

Goerz, G., 10, 13, 114

Goldberg, D.J., 18, 20, 84

Goldfarb, A., 2

Goldman, M.P., 5, 9, 11, 12, 16, 17, 19, 33, 49, 169

Gold, M.H., 1, 9, 12, 16, 18, 20, 33, 47, 50, 53, 85, 97, 100, 101

Gonzalez, M.L., 178

Goulden, V., 33, 93

Granuloma annulare (GA)

PDT, 118–119

subcutaneous anesthesia, 119

Grapengiesser, S., 94

Gudmundsson, F., 94

Guo, H., 184

Gupta, A.S., 184

Gupta, G., 26, 66, 69–72

**H**

Haedersdal, M., 151

Hafner, J., 11

Háiná, D., 48

Haldin, C.B., 92

Hamilton, T., 162

Hammerberg, C., 162

Hanada, K., 100

Handsley, M.M., 184

Harrison, P.V., 128

Harto, A., 112, 115

Hausman, W., 2

Hegyi, J., 118

Hematoporphyrin purified derivative (HPD)

porphyrin subunits and by-products, 2

PpIX, 3

Hennink, W.E., 184

Henta, T., 10, 14

Hernández-Núñez, A., 113, 115

Herrmann, G., 114

He, Y.Y., 184

Hidradenitis suppurativa (HS)

described, 53

epidemiology

apocrine gland areas, 54

associated diseases, 54

histological findings, 55–56

lesions, 54–55

phases, 55

prevalence rates, 54

smoking and obesity, 54

follicular tetrad, 53–54

hydradenite phlegmoneuse, 53

treatment

acute disease phase and flare-ups, 56

medical management and hormonal intervention,

PDT, 56–59

psoriasis biologic medications, 56

surgical modalities, 56

Hilleman, M., 113

Hilleman, P., 113

Hofer, A., 10, 15

Hohenleutner, U., 10, 14

Homey, B., 150

Hone, D.C., 184

Hongcharu, W., 32, 33, 36, 93

Honigsmann, H., 10

Hopson, B., 49

Horfelt, C., 93

Horio, O., 49

Horio, T., 49

Houlihan, A., 11, 13

HPD. See Hematoporphyrin purified derivative

HPV. See Human papilloma virus

HS. See Hidradenitis suppurativa

Huang, L., 182

Huang, Y.Y., 182

Human immunodeficiency virus (HIV)

ALA-PDT and blue light source, 101–102

molluscum lesions, 98

Human papilloma virus (HPV), 97

Hunziker, T., 99

I

Iani, V., 150, 151

Ibbotson, S.H., 78, 150, 168

ICG. See Indocyanine green
Indocyanine green (ICG) absorption spectrum, 35
diode laser, 35
enlarged gland, 36
and methylene blue, 40

Intensity pulse light (IPL)
acne therapy
ALA-PDT, 34
light source, 34
melanin and hemoglobin, 37
and PDL, 34
activation, 168
ALA, 163
5-ALA, 84
vs. blue light sessions, 59
light therapy, 164
photodynamic treatment, 84
settings, 167
treatment, 164

Ioannidis, D., 116
IPL. See Intense pulse light
Isei, T., 49
Ishida, N., 11, 14
Ishii, T., 184
Itoh, Y., 10, 14

J
Jacobsen, G., 26
Jaén, P., 112, 115
Jahnke, A., 182
Jarratt, M.T., 19, 65, 67, 69–72
Jatsova, E., 100
Jeffes, E.W., 10, 12
Jeffes, W.J., 10, 14
Jemec, G.B., 118
Jesionek, A., 1, 92, 126
Jiskoot, W., 184
Jodblauer, A., 1
Jodlbauer, A., 126
Ju, M., 101
Juzenas, P., 107, 150, 151
Juzeniene, A., 150–152, 179

K
Kaneko, T., 100
Kang, H.Y., 112
Kang, S., 62
Kaplan, R., 10, 12
Karrer, S., 9, 10, 14, 19, 66, 69–71, 109, 111, 117, 118
Kaufman, J.E., 2
Kaufmann, R., 66, 69–72, 105–107
Kauvar, A.N., 50
Kennedy, C., 142
Kennedy, J.C., 2, 3, 9, 10, 15
Kenney, M.E., 184
Keohane, S., 26, 66, 69–72
Kerl, H., 10, 15
Key, D.J., 18, 21
Keymel, K.R., 179
Kim, B.J., 119
Kim, H.S., 11, 15
Kim, J.Y., 112
Kim, M.N., 119
Kim, Y.C., 112
Kligman, A.M., 54, 91
Klövekorn, W., 65, 67, 69, 70
Knuist, A.C., 93
Kongshoj, B., 129
Konig, K., 105–107
Konnikov, N., 11, 12, 16, 17
Korell, M., 113
Kroto, H.W., 183
Kurwa, H.A., 9–11, 14
Kwon, O.S., 11, 15

L
Lacour, J.P., 116
Lambert, J., 65, 68–70, 72
Landthaler, M., 10, 48, 109, 111, 117, 118
Lange, T.S., 114
Lani, V., 179
Larkö, O., 91
Lear, J., 26, 66, 69–72
LEDs. See Light-emitting diodes
Lee, E.S., 112
Lee, J.W., 119
Lehmann, P., 150
Lesar, A.E., 150, 153
Lewis, J.B., 91
Liang, J., 101
Lichen planus, 110, 113
Lichen sclerosis treatment
ALA and PDT, 113
clinical studies, PDT, 114–116
extragenital, 114
MAL-PDL, 114
PpIX fluorescence, 113
recalcitrant, 113
Light-emitting diodes (LEDs)
ALA, 186–187
phototherapy and infrared (IR), 187
plaque psoriasis, 187
Liposomes, 184–185
Liposomes loaded methylene blue (LMB), 185
Lloret, A., 117
Lloyd, J., 36, 38
LMB. See Liposomes loaded methylene blue
Lock-Andersen, J., 100
Long-pulsed pulsed dye laser (LP DPL), 186, 188
Lorente, M., 18, 21, 117
Loss, R., 65, 67, 69–72
Lovat, L.B., 133
Lowe, N.J., 18, 19, 67, 69, 70
Lowe, P., 18, 19
LP DPL. See Long-pulsed pulsed dye laser
Lucky, A.W., 67, 69, 70
Lui, H., 107
MAL-PDT, AKs
ALA-PDT controlled study, 73–74
cryotherapy-controlled studies, 72–73
data extraction, 64
description, 62–63
limitations, 74
mechanism, 63
methodological analysis, 71–72
outcome measures
primary, 64
secondary, 64
patient preparation, 63
placebo-controlled studies, 72
results
included studies, 65, 71
methodological quality, 65, 69–70
studies included, 65–68
risk assessment, 64–65
search methods, studies identification
electronic searches, 63–64
inclusion and exclusion criteria, 64
other resources, 64
participant types, 64
types of studies, 63
MAL-PDT. See Methyl aminolevulinate photodynamic therapy
MAL-PDT, AKs
MAL-PDT controlled study, 73–74
cryotherapy-controlled studies, 72–73
data extraction, 64
description, 62–63
limitations, 74
mechanism, 63
methodological analysis, 71–72
outcome measures
primary, 64
secondary, 64
patient preparation, 63
placebo-controlled studies, 72
results
included studies, 65, 71
methodological quality, 65, 69–70
studies included, 65–68
risk assessment, 64–65
search methods, studies identification
electronic searches, 63–64
inclusion and exclusion criteria, 64
other resources, 64
participant types, 64
types of studies, 63
Ma, L.W., 150, 151
Manganiello, L.D.J., 2
Marie Wennberg, A., 91
Markham, T., 11, 14
Marmur, E.S., 18, 20, 84
Marsili, M., 48
Martin, G., 123
Martino Neumann, H.A., 184
Master, A.M., 184
Mastrobattista, E., 184
Matheson, R.T., 65, 67, 69, 70
Matrix metalloproteinases (MMPs)
ALA-PDT, 117
photosensitization, scleroderma fibroblasts, 114
Maxwell, P., 116
McClaren, M., 48
McCluggage, W.G., 116
McCullough, J.L., 10, 12, 14
McLean, D.I., 106, 107
Melendez, J., 117
Methyl aminolevulinate (MAL)
ALA, 85–86, 124
higher lipophilicity, 85
HS treatment
combination therapy, 58–59
Mettvix®, 58
occlusion drug incubation, 59
nail psoriasis treatment, 110
nonhyperkeratotic AKs treatment, 57
phototoxicity reactions, 85
PpIX absorption spectrum, 57, 58
red light rejuvenation
improvement, 86
Mettvix-PDT rejuvenation, 86
results, 86–87
red light use, 131
skin cancer prevention
large skin surfaces, 144
occlusion, 146
pain management, 143
porphyrins accumulation, 141
product monograph, 142
transplant patients, 141–142
skin cancers
BCC, 77–79
Bowen’s disease and SCC, 80
description, 77
non-melanoma skin cancers, 80
topical application and structure, 124
treatment
AA, 119
Lichen sclerosis, 114
NLD, 118
Sarcoidosis, 118
Vitiligo, 117
Methyl aminolevulinate photodynamic therapy (MAL-PDT)
acne vulgaris
MAL concentrations, 178
Mettvix® protocol, 177–178
treatment-specific problems, photosensitizer, 178
use, 178
and ALA-PDT, 174
definition, 173
drawback, 174
Galderma Mettivix® protocol, 173–174
pain association, 178–179
red light vs. purple light, 179
response rates, NMSC, 178
skin cancer
aftercare, 177
AKs and sBCCs, 174
application, MAL cream, 175
cream wiping, 175
documentation, 175–176
guidelines, 177
lesion preparation, 174, 176
light source and illumination scheme, 175, 176
noncoherent red light, 175
occlusion, adhesive and light protective dressing, 175
pain management, 176–177
pretreatment structure, Bowen’s disease, 174
treatment response, 177
Metvix® protocol, 177–178
Meyer-Betz, F., 2
Mikolajewska, P., 179
Millán, F., 18, 21, 117
Mills, W., 35
Mirkov, M., 36
Miyauchi-Hashimoto, H., 49
Mizuki, D., 100
MMPs. See Matrix metalloproteinases
Moan, J., 150, 151
Moiin, A., 101
Molluscum lesions
HIV disease, 98, 101
treatment
ALA-PDT use, 100
blue light source, 101–102
in vivo and in vitro analyses, 99
Moloney, F.J., 68–70
Mona, S., 184
Morhenn, V., 11, 13, 16, 17
Morken, T., 67, 69, 70, 72, 151
Morphea/scleroderma
ALA and incoherent light, 114
ALA-PDT, 117
histological examination, 117
MMPs, 114, 117
Morton, C.A., 10, 66, 69–72
Morton, S., 26
Moseley, H., 10, 11, 14, 150,
153, 168
Murrell, D.F., 78
N
Nakano, A., 11, 14
Nanotubes, 183
Na, R., 86, 99, 150
Necrobiosis lipoidica diabeticorum (NLD)
biopsy-proven recalcitrant, 118
total healing, 118
Nestor, M.S., 34, 42, 50
Neumann, H.A.M.
Nguyen, R., 65, 67, 69–71
Nineomiya, Y., 10, 14
NLD. See Necrobiosis lipoidica
diabeticorum
NMSC. See Non-melanoma skin cancer
No, D., 48
Nonablative rejuvenation
fractional resurfacing, 84
goal, 83
infrared lasers, 84
visible light lasers
pigmented, 84
vascular, 84
Non-melanoma skin cancer (NMSC)
pain severity, 178
response rates, MAL-PDT, 178
Novelli, M.R., 133
O
O’Brien, S.C., 91
Odooevskaya, O.D., 35, 36
Ohuuki, M., 49
Oku, N., 184
Oleinick, N.L., 184
Orenstein, A., 99
Organ transplant recipients (OTR) population, 21–22
Orringer, J.S., 162
Ortel, B., 10
Ortonne, J.P., 116
Ozog, D., 26, 59
P
Palm, M., 5
Panagiotidou, D., 113, 115, 116
Paquette, A.D., 179
Paredes, B.E., 67, 69, 70, 72, 151
Pariser, R.J., 67, 69, 70
Passeron, T., 116
Patsatsi, A., 113, 115
Pe4. See Phthalocyanine 4
PDL therapy. See Pulsed dye laser (PDL) therapy
PDT. See Photodynamic therapy
PDT applications
acne
ALA and MAL, 187
lesional clearance rates, 187–188
recalcitrant cystic acne, 188
anti-bacterial
bioluminescent tags, 188–189
Corynebacterium minutissimum, 189
Eschericia coli, 189
Mycobacteria, 189
Staphylococcus, 189
anti-fungal, 189
anti-microbial, 188
hair treatment
blonde vellus hairs, 188, 189
disorders, 188
intrapitoneal ALA injection, 188
PDT, skin cancer
action mechanism
immune response, 140
specific and non specific phototoxic effects, 141
clinical studies
non immunosuppressed patients, 142
transplant patients, 141–142
drawbacks
large skin surfaces, 144
outside the face, 144
pain, 143
photosensitivity and photoprotection, 144
realistic expectations, 144–145
etretinate and acitretin, 143
5 fluorouracil and imiquimod, 142–143
keratotic lesions, 142
Index

photosensitizer precursors, 139
preclinical studies, 141
Perez, B., 115
Pérez-García, B., 112
Phelps, R., 18, 20, 84
Philipson, P.A., 94, 178, 179
Photodamaged skin treatment
and AKs, 84
IPL, 84
molecular changes, 88
therapy, 88
type, 88–89
Photodynamic therapy (PDT). See also Methyl aminolevulinate photodynamic therapy (MAL-PDT)
AA, 119
acne
absorption spectrum, Pp IX, 92
acne vulgaris and sun exposure, 93
ALA and MAL, 93
armamentarium, 95
blue and red light, 93
description, 91
fluorescence, 92
light doses, 93
light sources, 92–93
pain and inflammation, 93–94
pain management, 95
practical aspects, 94
ALA
broadband visible light activation, 32, 33
IPL, 34
mechanism, 33
pioneers, 34–35
treatments, 33
applications, 187–189
approved drugs and light sources
ALA and MAL, 124
Levulan Kerastick® and Metvixia
Cream®, 124
Photofrin, 125
photosensitizer and porphyrin, 123–124
preparations, 124
topical applications, 124
ARMD, 133
Barrett’s esophagus (BE), 132–133
chronic X-ray dermatitis/radiodermatitis, 134
condylomata, 98, 101
cutaneous infections
bacterial, 126–129
fungal, 129–131
leishmaniasis, 131–132
cutaneous sarcoidosis, 134
Darier’s disease, 119–120
dermato-oncology care, 173
description, 97
DSAP, 132
GA, 118–119
HS
ALA and MAL, 57–59
indication, 56
photosensitizers, 56–57
indications, 87–88
inflammatory disorders, skin, 105
isotretinoin, 42
Lichen planus, 110, 113
Lichen sclerosis, 113–116
light sources
future, LEDs, 186–187
initial, 186
LP PDL, 186
portable/at-home, 187
recent, 186
Soret-band and lesser Q-band, 186
MAL used, 173
mechanism
ALA, 6
light irradiation, 6
light sources, 6–7
PpIX, 5–6
microtargeted delivery system, 190
molluscum lesions, 98, 101–102
Morphea/Scleroderma, 114, 117
NLD, 118, 135
paramecia cells, 1
photodynamic effect and topical 5% eosin, 1
photosensitizer delivery system
classification, 184
gold nanoconjugates, 185
liposomal delivery, 184–185
micelle delivery, 184
peptide nanocarriers, 185
silica nanoparticles, 184
photosensitizer development
classification, 182
fullerenes, 183
heme porphyrins, 182
phenothiazines, 183
phthalocyanines, 183
porphyrin, 181–182
pyroles, 182–183
photosensitizing agents and light sources, 123
photosensitizing compounds stimulation, 181
psoriasis, 105–110
pyogenic granuloma-like lesions, 134–135
sarcoidosis, 118
systemic photosensitizer
fluorescent light, 126
light sources and blue light, 125–126
Photofrin and Vetoporphin, 125
treatment, 99
use
ALA, 2
in dermatology, 2
heme biosynthetic pathway, 3
photosensitizers, 2
PpIX, absorption spectrum, 3
verrucae, 97–101
Vitiligo, 117
Photorejuvenation

efficacy, nonablative treatments, 84
MAL-red light
improvement, 86
Metvix-PDT rejuvenation, 86
results, 86–87
molecular changes, 88
nonablative rejuvenation, 83–84
PDT rejuvenation, 84–85
penetration improvement, 87
pulse-dye-laser (PDL), 84
treatment strategy, 88
ultrastructural changes, 84–85

Photosensitizer delivery systems
classification, 184
gold nanoconjugates, 185
liposomal delivery
BPD-MA and LMB preparation, 185
definition, liposomes, 184
spray and IPL, 185
micelle delivery
emulsification, 184
Pe4, 184
peptide nanocarriers, 185
silica nanoparticles
NaYF(4) upconversion nanocrystals, 184
Pe4, 184

Photosensitizer development
classification, 182
fullerenes, 183
heme porphyrins, 182
phenothiazines, 183
phthalocyanines, 183
porphyrin
approval, 182
systemic photosensitizers, 181–182
pyroles
classes, 182
description, 182
phaeophytin and phaeophorbide, 183
PPIX and chlorophyll, 182–183

Photosensitizers
acne therapy
activation, 36
advantage, 40
blue light status, 39
BLU-U device, 39
hair follicles, penetration, 40
ICG and methylene blue, 38
Levulan Kerastick treatments, 38–39
PDT effects, 40
Propionibacterium acnes killing, 39
SG and kinetics, 39–40
short contact, 40
acridine orange, 1
ALA, 2
cancer cells, 2
hematoporphyrin, 2
Protoporphyrin IX (PpIX), 2–3
topical 5% eosin, 1
Phthalocyanine 4 (Pe4), 183
Piacquadio, D.J., 11–13, 16, 17, 26, 168
Pillsbury, D.M., 91
Piraccini, B.M., 131
Placebo-controlled studies, 72
Plewig, G., 54
Pollock, B., 33, 57–58, 93
Pope, A., 100
Porflimer sodium
PDT use, 133
photosensitizing agent, 123
Porokeratosis (PK)
keratinization disorder, 166
malignant degeneration, 166
medical treatment, 166
Pottier, R.H., 2, 3, 9, 10, 15
PpIX. See Protoporphyrin IX
Prenzel, K., 114
Price, J.H., 116
Pross, D.C., 2, 3, 9, 10, 15
Protoporphyrin IX (PpIX)
absorption spectrum, 3, 57, 58
accumulation, psoriatic plaque, 106
fluorescence
AA, 119
Lichen sclerosis, 113
hair follicle epithelium, 57
heme pathway, 2–3
HPD, 3
MAL, 3
Pröve, F., 113
Psoriasis
action mechanism
ALA-PDT evaluation, 106
inflammatory cytokines, 105
PDT study results, 106, 107
clinical studies
5-ALA and broadband visible radiation,
108–109
filtered metal halide, 109
immunohistochemical evaluation, 109
Koebner phenomenon, 109
methylen blue use, 110
palmoplantar and nail, 110
PDT, 110, 111–112
SEI score, 108
uptake specificity
ALA-PDT evaluation, 106
keratolytic pretreatment, 106
PpIX accumulation, 106
Pulsed dye laser (PDL) therapy, 13, 98, 186
Pyogenic granuloma-like lesions
description, Goltz syndrome, 134–135
lesions and PDT, 135

Q
Qian, H., 184
Index

R
Raab, O., 1
Radakovic-Fijan, S., 9, 19, 66, 69–71, 109, 111
Raulin, C., 48
Rech, G., 131
Reifenberger, J., 66, 69–72
Reyes, M., 18, 21, 117
Rhee, C.K., 112
Riccardo, A., 99
Richey, D.F., 49
Rieger, E., 10, 15
Riley, P.A., 150
Rivard, J., 59
Roberts, J.E., 184
Robertson, D., 150
Robin, C., 53
Robinson, D.J., 106–108, 111
Robles, C.A., 107, 112, 156
Rodriguez, M.E., 184
Roelandts, R., 65, 68–70, 72
Romano, I., 78
Romero, A., 113, 115
Ros, A.M., 111
Rosdahl, I., 65, 68–70, 74, 94
Ruiz-Rodriguez, R., 11, 17, 19, 83, 84
Russell, D.A., 184
Ruzicka, T., 118, 150

S
Saalmann, G., 10, 13
Saksela, O., 67, 69, 70, 72, 151
Salah, M., 110, 112, 184
Salah, M., 110, 112, 184
Sánchez-Ronco, M., 112
Sandberg, C., 91, 92, 94
Sanz-Sánchez, T., 11, 17, 19, 84
Sarcoïdosis
ALA-PDT, 118
granulomatous lesions, 118
Sauerwald, A., 10
Sawayama, Y., 182
Scale, erythema and index (SEI) score, 108
SCC. See Squamous cell carcinoma
Scharffetter-Kochanek, K., 114
Schleyer, V., 109, 111
Schmid-Grendelmeier, P., 11
Schmidt, C., 48
Schönermark, M.P., 48
Sebaceous gland hyperplasia (SGH)
ALA-PDT
adverse events, 49
clinical evaluations, 50
drug incubation period, 50
nonhyperkeratotic AK lesions, 49
PDL, 49
recurrence rates, 50
tolerable incubation times, 49
cyclosporine, 47
description, 47
etiology, 48
size and activity, 47
treatment modalities
CO₂ lasers, 48
585-nm PDL, 48
oral isotretinoin, 48
postinflamatory hyperpigmentation, 49
Sebaceous glands (SGs)
absorption, 40
ICG
photosensitizer, 38
single patient, 36
PDL and IPL, 37
PpIX production, 33
Propionibacterium acnes killing, 39
Seddon, J.M., 184
Seed, P.T., 9, 10, 14
Selvasekar, C.R., 133
Serrano, G., 18, 21, 117
SGH. See Sebaceous gland hyperplasia
SGs. See Sebaceous glands
Shaffelburg, M., 15
Shapiro, J., 107
Sheehan-Dare, R.A., 106–108, 111
Shek, S.Y., 177
Shelley, W.B., 53, 91
Sies, H., 150
Sigurdsson, V., 93
Simonenko, G.V., 35, 36
Skin cancer prevention
ALA-PDT protocol
incubation time, 146
lesion biopsy, 145
MAL precursor, 146
phototoxic reaction minimization,
145–146
UV A lamp, 146
patient evaluation strategies, PDT
action mechanism, 140–141
clinical efficacy, 141–142
drawbacks, 143–145
modalities, 142–143
NMSC and AKs, 139–140
topical modalities, 140
PDT and photosensitizer precursors, 139
Skin fluorescence
aesthetic PDT, 158
linear correlation, application time, 152
Skiveren, J., 94, 178, 179
Smalley, R.E., 183
Smetana, Z., 99
Smith, S., 11, 13, 16, 17
Smits, T., 106–108, 112, 156
Smolle, J., 10, 15
Smucler, R., 100
Soler, A.M., 77
Sotiriou, E., 113, 115, 116
Spencer, J., 65, 67, 69–72
Squamous cell carcinoma (SCC)
  actinic keratosis, 166
  and Bowen’s disease, 80
  skin cancers, 161
Stables, G.I., 33, 57–58, 106–108, 111
Stahl, W., 150
Stefanaki, I.M., 101
Stege, H., 10, 13
Stender, I.M., 86, 99, 100, 150
Stenquist, B., 92, 94
Stewart, B., 17, 20, 84
Stewart, D.M., 19, 67, 69, 70
Strauss, R.M., 57–58
Stringer, M.R., 33, 93, 106–108, 111
Suthajariya, K., 32, 33, 36
Sutter, M., 184
Svanberg, K., 65, 68–70, 74
Szeimies, R.M., 9, 10, 19, 63–67, 69–72, 77, 78, 117, 118

T
Tajima, S., 10, 14
Talyor, J.R., 62
Tamada, Y., 11, 14
Tanew, A., 9, 19, 66, 69–71, 109, 111
Tang, H., 101
Tanzi, E.L., 17, 20, 49
Tappeiner, H., 92
Tarstedt, M., 65, 68–70, 74
Taub, A.F., 34, 40, 43, 105
Taylor, C.R., 32, 33, 36, 93
Taylor, J.R., 10, 12
Taylor, M.N., 178
Tempeler, R.H., 184
Terakawa, M., 182
Themelis, G.C., 101
Thorpe, S.M., 133
Tierney, E.P., 26
Torchilin, V.P., 184
Tosti, A., 131
Touma, D., 11, 12, 16, 17
Tremblay, J.F., 107
Tschen, E.H., 11, 13, 62
Tuchin, V.V., 35, 36
Turner, D., 33, 93

U
Untch, M., 113

V
van de Kerkhof, P.C., 106–108, 112, 156
van der Beek, N., 184
van Dongen, J.W.F., 9, 10
van Erp, P.E., 106–108, 112, 156
van Hell, A.J., 184
Vano-Galvan, S., 115
van Weelden, H., 9, 10, 93

Varma, S., 11, 14
Veleau, A., 53
Venturini, M., 10, 14
Verhaeghe, E., 66, 69–72
Verneuil, A., 53
Verrucae
  histology, 98
  HPV, 97
treatment
  ALA-PDT use, 99–100
  fractional laser resurfacing and ALA-PDT use, 100–101
  in vivo and in vitro analyses, 99
PDL and ALA, 100
Verteporfin
  ARMD, 133
description, 125
  photosensitizing agent, 123
  structure, 126
Vinciullo, C., 65, 67, 69–71
Vittiligo, 117
Von Tappeiner, H., 1, 126

W
Waidelich, W., 48
Warloe, T., 77
Watanabe, D., 11, 14
Weiderer, P., 117
Weightman, W., 66, 69–72
Weiland, G.S., 2
Weinstein, G.D., 10, 12, 14
Welch, E.C., 17, 20
Wennberg, A.-M., 65, 68–70, 74
Whitehead, S., 11, 12, 16, 17
Whitehurst, C., 10
Wieder, M.E., 184
Wiegel, S.R., 86, 93, 94, 129, 150, 151, 178, 179
Willemze, R., 142
Wilson, H., 11, 14
Wimmershoff, M.B., 118
Wlaschek, M., 114
Wolf, J.E.J., 62
Wolf, P., 10, 15
Wolterbeek, R., 142
Wong, D.S., 11, 13
Wulf, H.A., 178, 179
Wulf, H.C., 86, 93, 100, 129, 150, 151

Y
Yaar, M., 11, 12, 16, 17
Yeung, C.K., 177
Yin, J.J., 184
Yong-Gee, S.A., 9, 10, 14
Yoo, J.Y., 11, 15
Yoo, K.H., 119
Yu, C.C., 54
Index

Z
Zaki, I., 26, 66, 69–72
Zane, C., 9, 19, 66, 69–71
Zawislak, A.A., 116
Zelickson, B.

Zeng, H., 106, 107
Zhang, Y., 184
Zhao, B., 184
Zhiyentayev, T., 182
Zwingers, T., 109, 111